A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2017
At a glance
- Drugs E 6742 (Primary)
- Indications Cancer; Neurological disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eisai Inc
- 07 Nov 2017 Planned number of patients changed from 48 to 56.
- 07 Nov 2017 Planned End Date changed from 1 Aug 2017 to 21 Nov 2017.
- 07 Nov 2017 Status changed from recruiting to active, no longer recruiting.